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 Abstract 
 
Aim 
To assess the diagnostic accuracy of Contrast Enhanced Spectral Mammography (CESM), and gauge 
its “added value” in the symptomatic setting. 
Methods 
At our institution, women aged 35-70 years with a suspicious or malignant clinical abnormality are 
offered CESM instead of standard Full-Field Digital Mammography (FFDM) as an initial imaging test.  
CESM is also offered to younger women whose ultrasound is suspicious, or who have biopsy-proven 
malignancy. It is occasionally used as an alternative to breast MRI following multi-disciplinary team 
discussion.  
We performed a retrospective multi-reader review of 100 consecutive CESM examinations.  
Anonymised Low Energy (LE) images were reviewed and given a score for malignancy.  At least 3 
weeks later, the entire examination (LE and recombined images) was reviewed.  Pathology data was 
obtained for all cases.  Differences in performance were assessed using receiver 
operative characteristic (ROC) analysis. Sensitivity, specificity and lesion size (vs MRI or 
histopathology) differences were calculated. 
Results  
73% cases were malignant at final histology, 27% were benign following standard triple assessment. 
ROC analysis showed improved overall performance of CESM over LE alone, with area under the 
curve of 93% vs 83% (p<0.025).  CESM showed increased sensitivity (95% vs 84, p<0.025) and 
specificity (81% vs 63%, p<0.025) compared to LE alone, with all 5 readers showing improved 
accuracy.   Tumour size estimation at CESM was significantly more accurate than LE alone, the latter 
tending to undersize lesions.  In 75% of cases CESM was deemed a useful or significant aid to 
diagnosis. 
Conclusion 
CESM provides immediately available, clinically useful information in the symptomatic clinic in 
patients with suspicious palpable abnormalities.  Radiologist sensitivity, specificity and size accuracy 
for breast cancer detection and staging are all improved using CESM as the primary mammographic 
investigation.   
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Introduction 
 
The diagnostic assessment of patients with breast symptoms is based on the 
multidisciplinary triple diagnostic method.  This includes clinical assessment, 
imaging assessment and (where appropriate) needle biopsy (1).  
Mammography is the initial investigation of choice in women over the age of 
forty, and is also recommended in the assessment of younger women if 
clinically suspicious or malignant. 
Mammography has its limitations, particularly in the younger woman, with 
denser breasts, where sensitivity is reduced (2).  Contrast Enhanced 
Mammography (CESM) is a novel technique combining the benefits of 
iodinated contrast with standard mammographic views.  Dual energy 
acquisitions during one mammographic exposure yield two sets of images - 
a Low Energy (LE) set, equivalent to standard Full Field Digital Mammography 
(FFDM) (3) (4) (5) and a recombined set displaying contrast uptake.  Despite 
encouraging data from Europe and North America demonstrating increased 
sensitivity and specificity of the technique over FFDM (3) (6) (7), there is only 
limited data to support its routine use as a tool in the diagnosis and staging of 
breast cancer. 
Accurate local staging of breast cancer is important for treatment planning and 
prognostication.  With the increase in availability of oncoplastic techniques, 
the demonstration of multifocal or multicentric disease means that patients 
previously advised to undergo mastectomy may now be offered breast 
conserving surgery.  Larger tumours, previously warranting mastectomy, may 
be suitable for breast conserving surgery post neoadjuvant chemotherapy 
(NAC).  Knowing the size and location of tumour foci aids surgical planning.   
The aim of this study was to assess the diagnostic accuracy of CESM, and to 
assess its “added value” in the symptomatic setting.  
Method 
 
Since November 2013, CESM has routinely been performed in the symptomatic 
breast service at our institution, according to local departmental guidelines.  
All patients seen in our one-stop symptomatic clinics are examined by a 
surgeon or specialist nurse practitioner, prior to undergoing any imaging.  The 
clinical examination is graded as P1 - Normal, P2 - Benign, P3 - Indeterminate, 
P4 – Suspicious, and P5 - Malignant (1). Women aged 35-70 years with a 
suspicious or malignant (P4 or P5) clinical abnormality are offered 
CESM instead of FFDM as an initial imaging test.  CESM is also offered to 
younger women whose ultrasound is suspicious, or who have biopsy-proven 
malignancy. It is occasionally used as an alternative to breast MRI, for example 
if the patient is claustrophobic, following multi-disciplinary team (MDT) 
discussion.  
Renal function is not routinely available for patients attending symptomatic 
breast clinic, so we have taken a pragmatic approach and do not perform 
CESM in patients at increased risk of renal impairment.  This includes patients 
age >70 years, diabetics and anyone with a history of renal disease.  Patients 
with previous reaction to iodinated contrast agents, known iodine allergy and 
patients who are pregnant or lactating are also excluded from CESM. 
The CESM examination was performed on a commercially available system 
(Senobright, GE Healthcare). All patients undergoing CESM gave written 
consent for the procedure.   
In order to assess the diagnostic accuracy of CESM in the symptomatic setting 
a retrospective, multi-reader study was undertaken of our first 100 
consecutive CESM examinations comparing LE images alone, to the entire 
CESM examination (i.e. LE and recombined images).  Ethics approval was not 
deemed necessary, following discussion with our local Research and 
Development Team as this retrospective review was considered to represent 
audit of current clinical practice. 
Five fellowship-trained Consultant Radiologists read each of the 100 cases 
independently.  The CESM examinations were anonymised and displayed on a 
5 Megapixel mammography-approved workstation. Each reader had between 
eight and twenty-five years’ breast imaging experience and fulfilled the 
NHSBSP Quality Assurance Criteria for screening mammography film reading 
and assessment. 
Initially the LE images were read in isolation, scoring any abnormalities using 
the UK Royal College Of Radiologists Breast Imaging Classification scale (where 
1 is normal, 2 is benign, 3 is indeterminate, 4 is suspicious and 5 is malignant 
(8)). At least 3 weeks later, the process was repeated, viewing both the LE and 
the recombined images together.  Brief, anonymized, clinical information was 
available to the readers for both reads, for example “Patient feels lump left 
upper outer quadrant”. The radiologists were blinded to the final outcome and 
diagnosis in each case.   
The radiologists were asked to rate the usefulness of the recombined images in 
their decision-making on a 3 point scale, where 1= no added value, 2 = useful 
aid to diagnosis, 3 = significant aid to diagnosis. 
Pathology data was obtained for all women undergoing biopsy and for any 
subsequent surgery.  Histopathology provided the definitive ground truth for 
those subject to biopsy.   
For patients undergoing NAC, baseline MRI has remained our standard practice 
and therefore, in this group, tumour size was compared with reported size at 
baseline MRI.  Breast MRI examinations were performed according to the 
standard local protocol on a GE 1.5T scanner, using a dedicated breast coil. 
Where patients had surgery as their initial therapy, size was compared with 
reported histopathological (whole tumour) size.   
Differences in performance were assessed using receiver operative 
characteristic (ROC) analysis.  The symptomatic lesion, as documented in the 
clinical information provided, was deemed to be the “index lesion” in all cases.  
For ROC analysis, the highest score assigned to each breast was taken as the 
overall opinion – for example, where two lesions were described in one breast, 
the more suspicious lesion was used.  Sensitivity and specificity were analysed 
using 2-way independent t-test. Comparison of lesion size with MRI or 
histopathology was done using a t-test. A p value of <0.05 was regarded as 
statistically significant.   
  
Results 
 
Between November 2013 and September 2014, one hundred CESM 
examinations were performed in ninety-nine female individuals.  
98 examinations were bilateral.  1 patient underwent unilateral CESM due to a 
previous mastectomy.  1 patient had previously had a reaction to gadolinium at 
baseline MRI and so underwent unilateral CESM to assess residual tumour size 
post NAC in addition to the bilateral CESM examination performed at the time 
of diagnosis.  
The mean age of the patient group at the time of CESM was 48.6 years (range 
25 – 69 years).  The CESM examination was well tolerated by the patient group 
although one individual ‘collapsed’ during the CESM examination – this was 
treated initially as anaphylaxis, although subsequent investigations revealed 
underlying cardiac problems.  The patient recovered fully. 
The final diagnosis and outcome in each case is shown in Fig.1.  There were 73 
malignant cases and 27 with a benign final outcome.  Of the malignant cases, 
70 were invasive cancers, 2 were ductal carcinoma in situ and one was a 
papillary carcinoma.  In the benign group, the commonest cause for a clinically 
suspicious area with subsequent benign diagnosis was a cyst (11/27, 41%).   A 
case with both benign and malignant pathology is shown in figure 2. 
Blind Retrospective review  
 
ROC analysis showed overall performance when reviewing the entire CESM 
study (LE and recombined images) was significantly better than LE images 
viewed alone (Fig.3), with area under the curve of 93% vs 83% (p<0.025). 
Table 1 shows sensitivity and specificity for LE and CESM examinations.  The 
complete sensitivity (malignant cases rated 3, 4 or 5) was improved as was the 
specificity (benign cases rated 1 or 2) when the entire CESM study was 
reviewed.  Each of the five readers showed improved sensitivity and specificity 
when reviewing the entire CESM study. 
MRI examinations were performed in 30% of cases (30/100).  These were 
usually performed as a baseline prior to NAC, although four of these cases 
went on to have primary surgical treatment.  Figures 4 and 5 show the level of 
agreement between CESM and the tumour size at MRI or histopathology.  For 
those cases where an MRI was performed, the difference between CESM size 
and MRI size was significantly reduced compared to the LE images alone 
(p<0.001).  For the 46 cases that had primary surgical excision, there was also a 
significant reduction in the size difference between CESM and histological size 
compared to the LE images alone (p<0.0001).  LE images interpreted alone 
tended to underestimate tumour size. 
The results of the readers rating of the usefulness of the recombined image in 
the interpretation of the CESM study is show in figure 6.  Overall (using 
combined reader scores), the addition of the recombined images was deemed 
a useful aid to diagnosis in 40% cases and a significant aid to diagnosis in 35%. 
False Negative and False Positive Cases during Clinical Use 
 
There were four false-negative CESM examinations in the study group.  Two 
patients had CESM reported as normal, but the area of concern in each case 
was off the mammographic field (one patient had pectus excavatum).  Triple 
assessment in both cases yielded a malignant diagnosis (both areas were 
palpable and also evident at ultrasound). A third patient had a CESM 
examination following C5 cytology taken at ultrasound.  This showed no 
abnormality, but a 4mm lobular carcinoma was found at surgical excision.  
The fourth patient had a cancer diagnosed 14 months after the initial CESM 
examination.  Low energy views were benign and recombined views showed 
subtle patchy linear enhancement in the area of clinical concern.  A freehand 
core biopsy at this time was benign - B2 with inflammatory changes.   The 
patient re-presented with increasing symptoms and a repeat CESM (not 
included in this review) showed florid and extensive enhancement.  Core 
biopsy showed a high nuclear grade, well-circumscribed encapsulated papillary 
carcinoma – B5C. 
There was one false positive CESM case.  A focal area of suspicious 
enhancement was demonstrated at the site of clinical concern at CESM, but 
triple assessment including ultrasound guided core biopsy showed fat necrosis. 
  
Discussion 
 
In this study, the routine use of CESM as the first line mammographic modality 
for a symptomatic patient population with clinically suspicious abnormalities 
led to a significant improvement in diagnostic accuracy.  Other groups have 
also recognised the value of CESM in cancer detection.  Several studies have 
demonstrated consistent superiority of CESM when compared to FFDM (9) (10) 
(11) (12).  Cheung et al (10) reported 89 women undergoing both CESM and 
conventional mammography. They concluded that CESM provided additional 
information over mammography, with consistent improvement of cancer 
diagnosis especially in women with a dense breast parenchymal pattern.  
In our symptomatic practice, CESM consisting of the low energy image and a 
recombined image has replaced conventional FFDM in patients presenting with 
clinically suspicious abnormalities.  The low energy images generated during 
the CESM exam have previously been shown to be equivalent to standard 
FFDM (3) (4) .  Fallenberg’s group (3) compared FFDM with CESM alone and 
with CESM plus FFDM, looking at the detection and size estimation of 
histologically proven breast cancers in 118 women. CESM alone had the same 
sensitivity and better size assessment as CESM plus FFDM and was significantly 
better than FFDM alone. CESM alone also had the closest correlation with 
pathological size.  Interestingly they found that when FFDM images where 
available in addition to CESM this led to a systematic overestimation of the 
average lesion size.  They concluded that when a CESM examination is 
undertaken additional mammography with FFDM can be avoided.  This is the 
approach adopted in our practice, enabling patients to benefit from the 
improved diagnostic accuracy of CESM, without the extra radiation dose of an 
additional FFDM examination.  The radiation dose of CESM (to include both the 
LE and high energy components) is higher than FFDM, with reported increase 
in average glandular dose of between 6 and 81% (3) (13) (14).  However, the 
doses recorded in these studies still met the recommendations for maximum 
dose in mammography. 
In the past, concern has been raised regarding potential obscuration of 
microcalcifications on the LE images due to the administration of contrast 
agent.  This is an important consideration if conventional FFDM is to be 
omitted from the imaging pathway.   It has been shown that calcifications are 
actually better visualised on the LE component of a CESM examination than on 
standard FFDM (15).  It should be remembered that the CESM exam consists of 
two sets of images, both of which require equal attention – calcification may 
be obvious on the LE images, but not enhance on the recombined views.  If 
calcifications are deemed suspicious on the LE views, they should be worked 
up in the same way as if they had been seen on standard FFDM. 
30% of the patient in our series also underwent MRI examination.  This was 
typically performed in patients who were candidates for neo-adjuvant 
chemotherapy.  Our local protocol continues to use MRI to monitor response 
to neoadjuvant chemotherapy - little work has been done to investigate a 
potential role for CESM in this setting. MRI can be a useful tool in staging 
breast cancer, particularly in patients diagnosed with lobular carcinoma or 
mammographically occult tumours (16). The use of MRI has the potential to 
delay the diagnostic process.  Scanner time and availability is often an issue.  If 
additional lesions are identified, a “second-look” ultrasound and perhaps 
further biopsy (either ultrasound or MR-guided) may be required.  The great 
strength of using CESM as the first line mammographic investigation is that 
additional staging information and any further biopsies can be obtained at the 
first patient visit.  In our study, CESM better reflected both MRI and 
histopathological size.  Accuracy was much improved compared to the LE 
portion of the study alone which tended to underestimate tumour size.  Others 
have also found good agreement between CESM, MRI measurements and 
histopathology (6) (7) (12) (17). 
 
Since the premise of CESM is to identify abnormal enhancement within the 
breast, there is concern that the technique may identify lesions which are not 
of clinical relevance and potentially lead to “overtreatment” of disease.  An 
increase in mastectomy rates has been attributed to the same mechanism in 
centres routinely performing breast MRI for staging.  This concern has not 
been borne out in the initial clinical experience of CESM.  Lobbes et al. in a 
study of 113 CESM examinations performed in women recalled from the Dutch 
screening programme found that MRI detected more ipsilateral additional foci 
of tumour cells in women diagnosed with a breast cancer (88% of additional 
foci were detected using MRI compared to 56% with CESM) (7).  However, 
CESM resulted in fewer false positives - 13 false positives were observed at 
MRI, compared to only two false-positives using CESM.  The number of 
multifocal tumours undergoing MRI in our series was too small to make any 
meaningful comparison with CESM.  There was one false positive case in our 
own series with a focal area of suspicious enhancement demonstrated at the 
site of clinical concern on CESM, with percutaneous biopsy demonstrating fat 
necrosis.  As with MRI it is important that the nature of abnormal areas of 
enhancement is determined with percutaneous biopsy before treatment 
decisions are made.  Further work is still needed before CESM can be 
recommended as a replacement for MRI. 
Clearly CESM takes longer to perform than a standard mammogram.  Most of 
this additional time is taken in patient consent, excluding contraindications and 
establishing intravenous access. We estimate that this adds approximately 10-
15 minutes per exam.  These tasks could be delegated to mammography staff 
with appropriate training.  Once the patient is in the room and the injection 
has been given, the mammographic technique is identical to standard FFDM.  
The images can be reviewed immediately and any further areas of concern can 
be investigated during the same clinic appointment.  
The administration of iodinated contrast agents is not completely without risk.  
We do not administer contrast agent to patients who have or at risk of renal 
impairment.  The potential for contrast agent toxicity needs to be considered.  
All staff involved in contrast administration have had the appropriate training 
to recognise and treat contrast agent reactions, with the necessary drugs and 
resuscitation equipment immediately available.  We had one potential contrast 
agent reaction in this series of our first 100 cases, but on further investigation 
this may well have been cardiac in origin rather than true anaphylaxis. 
The CESM technique is generally well-accepted by staff and patients.  Hobbs et 
al (18) looked at the patient experience of CESM compared with MRI during 
preoperative breast cancer staging. A significantly higher overall preference 
towards CESM was demonstrated, with patients citing faster procedure time, 
greater comfort and lower noise levels. Participants also reported lower rates 
of anxiety during CESM compared with CEMRI.  In our study, the reporting 
radiologists also found CESM to be a useful tool.  In 75% of cases CESM was 
deemed a useful or significant aid to diagnosis. 
There are limitations to this study. The majority of patients undergoing CESM 
had a clinically suspicious abnormality; consequently the case-mix is skewed 
towards larger tumours.  Research suggests that sizing of larger tumours is less 
accurate, with CESM tending to oversize compared to MRI (7) (19). 
Consequently it may not be possible to extrapolate the findings to other 
patient groups were tumours may be smaller.  Further work is needed in other 
symptomatic and screening populations.   In addition, although this multi-
reader study was blinded, the readers knew that the patients were 
symptomatic, and were also aware of the site of clinical concern.  We have a 
taken a pragmatic approach and although this may result in bias the CESM 
study was interpreted as it would be in clinical practice.   
In conclusion, CESM provides immediately available, clinically useful 
information in the symptomatic clinic in patients with suspicious palpable 
abnormalities.  Radiologist sensitivity, specificity and size accuracy for breast 
cancer detection and staging are all improved using CESM as the primary 
mammographic investigation.  The routine use of the technique in other 
settings still requires further evaluation. 
 
 
  
 Fig.1  Final diagnosis and outcome 
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 Table 1 Individual Reader Performance 
 
 
 
Fig.3 Overall Performance of CESM vs LE alone 
 
 
LE CESM LE CESM
R1 89.0% 93.2% 70.4% 74.1%
R2 84.9% 91.8% 70.4% 85.2%
R3 86.3% 94.5% 51.9% 81.5%
R4 84.9% 95.9% 59.3% 81.5%
R5 76.7% 97.3% 63.0% 81.5%
Mean 84.4% 94.5% 63.0% 80.7%
p (t-test) 0.023 0.014
SpecificityComplete Sensitivity (M3,4,5)
 
 Fig.4 Size agreement between CESM and reported tumour size at MRI  
 
Fig.5 Size agreement between CESM and histopathology (whole tumour size) 
 
 
Fig.6 Reader-perceived usefulness of recombined views 
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Fig. 2  
A 46 year old female presented to clinic, having noticed lumps in both breasts.  
Clinical examination revealed a suspicious mass in the left breast (P5) and an 
indeterminate mass in the right breast (P3). 
Contrast mammography was performed.  LE images (A-D) show a dense 
background pattern.  There is a mass in the upper inner aspect of the right 
breast and some subtle distortion in the upper outer quadrant of the left 
breast. 
Recombined images (E-H) demonstrate the “eclipse” sign of a cyst within the 
right breast.  This was confirmed at ultrasound.  A large area of enhancement 
is seen in the upper left breast -  at least 50mm.  Ultrasound core biopsy 
proved grade 2 tumour with lobular features.  
MRI pre-NAC (I) showed approximately 60mm of enhancement within the left 
breast.  The right breast was benign at MRI. 
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